RESUMO
The synthesis and orexigenic activity of some unsubstituted and Bz-carboxylic acid substituted 1-methyl-4-piperidylidenepyrrolo[2,1-b][3]benzazepine and dibenzocycloheptene derivatives are described. 10,11-Dihydro-3-carboxycyproheptadine (7c) has been selected for clinical evaluation as a orexigenic agent based on its low threshold dose for increasing food consumption in cats (0.031 mg/kg po) and its lack of undesirable central nervous system activity. The levorotatory enantiomer of 3-carboxycyproheptadine (1d) and the 9-carboxypyrrolobenzazepine derivative 4f also possess orexigenic activity, but with these compounds such activity diminishes sharply below 0.25 mg/kg po. The unsubstituted 1-methyl-4-(5H-pyrrolo[2,1-b][3]benzazepin-11-ylidene)piperidine (4d) and its 6,11-dihydroanalogue (4a) are comparable to cyproheptadine (1a) in promoting hyperphagia in cats.
Assuntos
Apetite/efeitos dos fármacos , Benzazepinas/síntese química , Dibenzocicloeptenos/síntese química , Animais , Benzazepinas/farmacologia , Gatos , Fenômenos Químicos , Química , Ciproeptadina/farmacologia , Dibenzocicloeptenos/farmacologia , Ingestão de Alimentos/efeitos dos fármacos , Estimulação QuímicaRESUMO
Several hydrogenated derivatives of the potent NMDA antagonist 1 have been prepared and evaluated as competitive inhibitors of [3H]-1 binding. These compounds were also tested for their ability to act as noncompetitive antagonists of NMDA in vitro. These studies indicate that two aromatic rings are not strictly required for high-affinity binding or NMDA antagonism.
Assuntos
Anticonvulsivantes/farmacologia , Ácido Aspártico/análogos & derivados , Dibenzocicloeptenos/farmacologia , Animais , Ácido Aspártico/antagonistas & inibidores , Dibenzocicloeptenos/síntese química , Dibenzocicloeptenos/metabolismo , Maleato de Dizocilpina , Técnicas In Vitro , Conformação Molecular , N-Metilaspartato , Ratos , Receptores de N-Metil-D-Aspartato , Receptores de Neurotransmissores/efeitos dos fármacos , Relação Estrutura-AtividadeRESUMO
A systematic investigation was undertaken to determine the role of the P1' sidechain in a series of hydroxyethylene isostere based inhibitors of HIV-1 protease. Substitution and homologation of the benzyl P1' side chain of the Phe-Phe isostere based pseudo peptides 1 (L-682,679) and 2 (L-685,434) with various heteroalkyl groups leads to a series of extremely potent inhibitors of the enzyme. Several examples of the most potent inhibitors were very effective in an ex vivo cell based viral spread assay using human H9 T-lymphocytes and the IIIb isolate of HIV-1. Compound 19 is 120 times more potent than 1 and 16 times more potent than 2 in inhibiting the spread of infection in this assay.
Assuntos
Antivirais/farmacologia , Dipeptídeos/farmacologia , Etilenos/farmacologia , Inibidores da Protease de HIV , HIV-1/enzimologia , Antivirais/química , Dipeptídeos/síntese química , Dipeptídeos/química , Etilenos/síntese química , Protease de HIV/metabolismo , HIV-1/crescimento & desenvolvimento , Humanos , Indóis/química , Indóis/farmacologia , Oligopeptídeos/química , Oligopeptídeos/farmacologia , Fosfatos/química , Inibidores de Proteases/química , Inibidores de Proteases/farmacologia , Solubilidade , Relação Estrutura-Atividade , Linfócitos T/microbiologiaRESUMO
A series of 73 dibenzo[a,d]cycloalkenimines were synthesized and evaluated for their ability to displace (+)-10,11-dihydro-5-methyl-5H-dibenzo[a,d]cyclohepten-5,10-imine ([3H]-(+)-10) from its specific binding site on rat cortical membranes. A number of the more active compounds (Ki ranging from 0.006 to 0.21 microM) were evaluated for N-methyl-D-aspartate (NMDA) antagonist activity in the rat cortical slice (Kb ranging from 0.08 to 0.9 microM) and anticonvulsant activity in the mouse against NMDA induced convulsions. The ED50 values ranged from 0.22 to 7.76 mg/kg and correlated reasonably well with the Kb determination. In the dibenzo[a,d]cyclohepten-5,10-imine series, the (+)-5S,10R enantiomer displayed consistently higher levels of biological activity. While substitution at the 3-position of (+)-10 with electronegative atoms generally increased in vitro activity, a loss of potency relative to (+)-10 (MK-801) was observed in vivo for all of the compounds tested.
Assuntos
Anticonvulsivantes/síntese química , Ácido Aspártico/análogos & derivados , Iminas/síntese química , Compostos Policíclicos/síntese química , Receptores de Neurotransmissores/efeitos dos fármacos , Animais , Ácido Aspártico/antagonistas & inibidores , Ligação Competitiva , Córtex Cerebral/metabolismo , Fenômenos Químicos , Química , Desenho de Fármacos , Iminas/farmacologia , Técnicas In Vitro , Canais Iônicos/efeitos dos fármacos , Modelos Moleculares , N-Metilaspartato , Compostos Policíclicos/farmacologia , Ratos , Ratos Endogâmicos , Receptores de N-Metil-D-Aspartato , TermodinâmicaRESUMO
As part of an ongoing effort to prepare novel non-nucleoside inhibitors of human immunodeficiency virus type-1 (HIV-1) reverse transcriptase (RT), a series of 4-(arylethynyl)-6-chloro-4-cyclopropyl-3,4-dihydroquinazolin -2(1H)-ones 4aa-l has been prepared. Target compounds 4a-e were synthesized via addition of various 1-lithio-2-(aryl)alkyne nucleophiles to a 1-protected-4-cyclopropylquinazolin-2(1H)-one (7), followed by deprotection. The 3-methyl compound 4aa was prepared in an analogous manner, with the 3-alkylation performed prior to deprotection. Alternatively, the target compounds 4f-l were prepared by addition of 1-lithio-2-(trimethylsilyl)acetylene to 7, followed by deprotection and subsequent palladium-catalyzed coupling with various aryl halides. By incorporating an aryl group onto the end of the 4-acetylene functionality, the requirement for a metabolically labile 3-methyl group on the dihydroquinazolinone nucleus has been eliminated. A number of the target compounds were shown to be potent inhibitors of HIV-1 RT. Compound 4a, which had exhibited the most favorable overall biological profile, was resolved via a four-step procedure to provide the enantiomers 13a and 13b. Compound 13a having the (-)-4(S) configuration was shown to be the active enantiomer and was selected as a candidate for further investigation.
Assuntos
HIV-1/enzimologia , Quinazolinas/farmacologia , Inibidores da Transcriptase Reversa , Células Cultivadas , Cristalografia por Raios X , Transcriptase Reversa do HIV , Humanos , Quinazolinas/síntese químicaRESUMO
The synthesis of a series of 1-methyl-4-(9-substituted-11H-pyrrolo[2,1-b]benzazepin-11-ylidene)piperidines (4a-f) and 1-methyl-4-(9-substituted-6,11-dihydro-5H-pyrrolo[2,1-b][3]benzazepin-11-ylidene)piperidines (4g-l) is described. As with th e 3-substituted cyproheptadine compounds 1b-e, atropisomerism exists in 4b-f, but unlike the enantiomers of 1b-e, the pyrrolobenzazepine enantiomers racemize at room temperature. Thus, the bromo compound (+)-4b has a half-life of 128 +/- 1 min at 25 degrees C, while the chloro compound (-)-4c has a half-life of 114 +/- 9 min at 25 degrees C. Compounds 4a-l have been examined for receptor binding affinities in assays that have been recognized as predictive for antipsychotic activity. The displacement of specifically bound tritiated ligands, comprising the dopamine antagonist [3H]spiperone, the dopamine agonist [3H]apomorphine, the muscarinic cholinergic antagonist [3H]quinuclidinyl benzilate (QNB), the alpha-adrenergic antagonist [3H]prazosin, the alpha-adrenergic agonist [3H]clonidine, the serotonin-1 binding agent [3H]serotonin, and the mixed serotonin agonist-antagonist [3H]lysergic acid diethylamide (LSD), by 4a-l has been measured utilizing membrane preparations of mammalian brain. Certain of the features of the receptor binding of these compounds have been shown to be common to several of the receptor sites. Data from these binding studies have been compared to corresponding data previously obtained for a series of chiral 3-substituted cyproheptadine analogues, and the receptor binding data of the two classes of compounds are discussed with respect to their molecular geometries.
Assuntos
Antipsicóticos/síntese química , Benzazepinas/síntese química , Piperidinas/síntese química , Receptores de Superfície Celular/metabolismo , Animais , Benzazepinas/farmacologia , Ligação Competitiva , Bioensaio , Encéfalo/metabolismo , Membrana Celular/metabolismo , Piperidinas/farmacologia , Receptores de Superfície Celular/efeitos dos fármacos , Relação Estrutura-AtividadeAssuntos
Aminoácidos/farmacologia , Antifibrinolíticos/farmacologia , Hidrocarbonetos Aromáticos com Pontes/farmacologia , Aminoácidos/síntese química , Antifibrinolíticos/síntese química , Hidrocarbonetos Aromáticos com Pontes/síntese química , Fenômenos Químicos , Química , Fibrinólise/efeitos dos fármacos , HumanosAssuntos
Ácido Gástrico/metabolismo , Antagonistas dos Receptores H2 da Histamina/síntese química , Tiadiazóis/síntese química , Ureia/análogos & derivados , Animais , Ligação Competitiva/efeitos dos fármacos , Fenômenos Químicos , Química , Cimetidina/farmacologia , Di-Hidrotestosterona/metabolismo , Cães , Cobaias , Técnicas In Vitro , Camundongos , Contração Muscular/efeitos dos fármacos , Ratos , Estereoisomerismo , Tiadiazóis/farmacologia , Difração de Raios XRESUMO
The clinical benefit of the human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase (RT) inhibitors (NNRTIs) is limited by the rapid selection of inhibitor-resistant viral variants. However, it may be possible to enhance the clinical utility of this inhibitor class by deriving compounds that express both high levels of antiviral activity and an augmented pharmacokinetic profile. Accordingly, we developed a new class of NNRTIs, the 1, 4-dihydro-2H-3, 1-benzoxazin-2-ones. L-743, 726 (DMP-266), a member of this class, was chosen for clinical evaluation because of its in vitro properties. The compound was a potent inhibitor of the wild-type HIV-1 RT (Ki = 2.93 nM) and exhibited a 95% inhibitory concentration of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture. In addition, L-7743, 7726 was found to be capable of inhibiting, with 95% inhibitory concentrations of < or = 1.5 microM, a panel of NNRTI-resistant mutant viruses, each of which expressed a single RT amino acid substitution. Derivation of virus with notably reduced susceptibility to the inhibitor required prolonged cell culture selection and was mediated by a combination of at least two RT amino acid substitutions. Studies of L-743, 726 in rats, monkeys, and a chimpanzee demonstrated the compound's potential for good oral bioavailability and pharmacokinetics in humans.